State Street’s Pasithea Therapeutics KTTA Stock Holding History

State Street’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,182	Closed	-$11.6K	–	4575
2023 Q2	$11.6K	Hold	1,182	–	–	﹤0.01%	4638
2023 Q1	$9.2K	Hold	1,182	–	–	﹤0.01%	4747
2022 Q4	$15.4K	Hold	1,182	–	–	﹤0.01%	4766
2022 Q3	$30K	Hold	1,182	–	–	﹤0.01%	4761
2022 Q2	$24K	Buy	+1,182	New	+$25.2K	﹤0.01%	4853

Other funds holding KTTA

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

NGA

Naples Global Advisors Naples, Florida $1.62B AUM 47.65% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MSFP

Mark Sheptoff Financial Planning Glastonbury, Connecticut $189M AUM 28.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street's KTTA Position: Q3 2023 in Review

State Street sold out of Pasithea Therapeutics (KTTA) in Q3 2023, closing a stake of 1,182 shares — an estimated $11.6K sold.

State Street first reported a position in KTTA in Q2 2022 and held it in 5 quarters. The position peaked at $30K in Q3 2022. 12 funds tracked by Wall St. Rank hold KTTA as of Q3 2023.

State Street reported no remaining Pasithea Therapeutics position as of Q3 2023 after selling out during the quarter.
State Street sold 1,182 Pasithea Therapeutics shares in Q3 2023, an estimated $11.6K.
State Street first reported a position in Pasithea Therapeutics in Q2 2022 and held it in 5 quarters.
State Street's Pasithea Therapeutics position peaked at $30K in Q3 2022.
12 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.